Antidepressant efficacy of 5-HT<sub>1A</sub> partial agonist drugs

Donald S. Robinson

in 5-Hydroxytryptamine in Psychiatry

Published in print February 1991 | ISBN: 9780192620118
Published online March 2012 | e-ISBN: 9780191724725 | DOI:
Antidepressant efficacy of 5-HT1A partial agonist drugs

Show Summary Details


Buspirone's initial clinical development involved treatment of chronic anxiety in patients generally corresponding to the DSM-III. Dysfunction of central serotonergic neuronal systems is implicated in mood disorders, and treatment of these disorders has recently been focused on this neurotransmitter. The 5-HT1A partial agonists possess a pharmacological profile predictive of both antidepressant and anxiolytic activity. Placebo-controlled studies with buspirone and gepirone in depressive disorders have shown that these agents produce significant therapeutic benefit. Buspirone and gepirone treatment resulted in global improvement of depressed patients, and specifically benefited symptoms of depressed mood, work and activity, anergia, diurnal variation, and other cardinal symptoms of depression.

Keywords: buspirone; anxiolytic; anti-anxiety drugs; chronic anxiety; serotonergic neuronal systems; neurotransmitter; antidrepressant

Chapter.  3025 words.  Illustrated.

Subjects: Neuroscience

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.